<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105152</url>
  </required_header>
  <id_info>
    <org_study_id>PLAT-08</org_study_id>
    <nct_id>NCT05105152</nct_id>
  </id_info>
  <brief_title>PLAT-08: A Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML</brief_title>
  <official_title>Pediatric And Young Adult Leukemia Adoptive Therapy (PLAT)-08: A Phase 1 Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>bluebird bio</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with&#xD;
      relapsed or refractory CD33+ leukemia with and without prior history of allogeneic&#xD;
      hematopoietic cell transplantation, to examine the safety and feasibility of administering an&#xD;
      autologous T cell product that has been genetically modified to express a Dimerizing Agent&#xD;
      Regulated Immunoreceptor Complex (DARIC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2039</completion_date>
  <primary_completion_date type="Anticipated">February 29, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase I open-label, dose-finding study employing the Bayesian optimal interval (BOIN) design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events associated with SC-DARIC33 cell product infusions will be assessed</measure>
    <time_frame>28 days post-infusion</time_frame>
    <description>The type, frequency, severity, and duration of adverse events will be summarized</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ability to successfully manufacture SC-DARIC33</measure>
    <time_frame>28 days</time_frame>
    <description>Measure of the number of successfully manufactured SC-DARIC33 products</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Myeloid Leukemia response to SC-DARIC in subjects with relapsed or refractory CD33+ myeloid leukemia will be assessed</measure>
    <time_frame>28 days post-infusion</time_frame>
    <description>The efficacy of the SC-DARIC33 assessed based on the bone marrow aspirate testing following SC-DARIC infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Myeloid Leukemia Refractory</condition>
  <condition>Acute Myeloid Leukemia, in Relapse</condition>
  <arm_group>
    <arm_group_label>DARIC-33</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SC-DARIC33</intervention_name>
    <description>Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration</description>
    <arm_group_label>DARIC-33</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject age ≤ 28 years. The first three enrolled subjects must be ≥ 18 years of age.&#xD;
&#xD;
          2. AML that expresses CD33 by flow cytometry and meets one of the below definitions:&#xD;
&#xD;
               1. For subjects who have previously received an allogeneic HCT, any evidence of AML&#xD;
                  re-emergence post HCT detectable by flow cytometry&#xD;
&#xD;
               2. First relapse of AML ≤ 6 months of initial diagnosis&#xD;
&#xD;
               3. First relapse of AML &gt; 6 months after initial diagnosis, with MRD of &gt;0.1% by&#xD;
                  flow cytometry (MPF) after at least one re-induction (single cycle) attempt&#xD;
&#xD;
               4. Second or greater relapse AML&#xD;
&#xD;
               5. Refractory AML, defined as &gt;1% leukemic cells determined by flow cytometry after&#xD;
                  2 cycles of induction chemotherapy&#xD;
&#xD;
          3. Able to tolerate apheresis, or subject with sufficient existing apheresis product or T&#xD;
             cells for manufacturing investigational product.&#xD;
&#xD;
          4. Life expectancy ≥ 8 weeks&#xD;
&#xD;
          5. Has an appropriate stem cell donor source identified&#xD;
&#xD;
          6. Lansky performance status score of ≥ 50 for subjects &lt;16 years of age or Karnofsky&#xD;
             score ≥ 50 for subjects ≥ 16 years. Subjects who are unable to walk because of&#xD;
             paralysis, but who are up in a wheelchair, will be considered ambulatory for purposes&#xD;
             of assessing performance status&#xD;
&#xD;
          7. If a subject does not have a previously obtained apheresis product that is acceptable&#xD;
             and available for manufacturing of DARIC T cells, the subject must discontinue all&#xD;
             anticancer agents and radiotherapy and, in the opinion of the investigator, have fully&#xD;
             recovered from significant acute toxic effects of all prior chemotherapy,&#xD;
             immunotherapy, and radiotherapy:&#xD;
&#xD;
             a. Chemotherapy and biologic agents: All chemotherapy and biologic therapy not&#xD;
             specifically mentioned below must be discontinued ≥ 7 days prior to enrollment, with&#xD;
             the exception of intrathecal chemotherapy for which there is not a required washout&#xD;
             period b. Must be ≥ 30 days from last gemtuzumab ozogamicin dose. c. Steroid use: All&#xD;
             corticosteroid therapy (unless physiologic replacement dosing) must be discontinued ≥&#xD;
             7 days prior to enrollment d. Tyrosine Kinase Inhibitor (TKI) use: All TKIs must be&#xD;
             discontinued ≥ 3 days prior to enrollment e. Hydroxyurea: must be discontinued ≥ 1 day&#xD;
             prior to enrollment. f. Gene Modified cellular therapy: i. must be at least 30 days&#xD;
             from most recent gene modified cell therapy infusion and document no evidence of&#xD;
             modified cells in the peripheral blood OR ii. must be at least 60 days from most&#xD;
             recent gene modified cell therapy&#xD;
&#xD;
          8. Adequate organ function as indicated by:&#xD;
&#xD;
               1. Renal: Serum creatinine ≤ 1.5 X the upper limit of normal (ULN)&#xD;
&#xD;
               2. Hepatic: Total bilirubin ≤ 3 times ULN for age OR conjugated bilirubin ≤ 2 mg/dL&#xD;
                  AND ALT (SGPT) ≤ 5 times ULN&#xD;
&#xD;
               3. Cardiac: Shortening fraction ≥ 28% OR ejection fraction ≥ 50% as measured by&#xD;
                  echocardiogram&#xD;
&#xD;
               4. Respiratory: Oxygen saturation ≥ 92% on room air without supplemental oxygen or&#xD;
                  mechanical ventilation&#xD;
&#xD;
          9. Laboratory values meet the following criteria:&#xD;
&#xD;
             a. Subjects requiring apheresis: Absolute Lymphocyte Count (ALC) ≥ 100 cells/uL b.&#xD;
             Virology Testing negative within 3 months prior to enrollment, to include: i. HIV&#xD;
             antigen &amp; antibody ii. Hepatitis B surface antigen iii. Hepatitis C antibody OR if&#xD;
             positive, Hepatitis C PCR is negative&#xD;
&#xD;
         10. If subject is of childbearing or child-fathering potential, must agree to use highly&#xD;
             effective contraception from the time of initial consent through 12 months following&#xD;
             the infusion of investigational product on this trial.&#xD;
&#xD;
         11. Subject and/or legally authorized representative has signed the Informed Consent Form&#xD;
             for this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active malignancy other than acute myeloid leukemia&#xD;
&#xD;
          2. History of symptomatic non-AML CNS disease or ongoing symptomatic CNS disease&#xD;
             requiring medical intervention, including paresis, aphasia, cerebrovascular&#xD;
             ischemia/hemorrhage, severe brain injury, dementia, cerebellar disease, organic brain&#xD;
             syndrome, psychosis, coordination or movement disorder (subjects with non-febrile&#xD;
             seizure disorder controlled on anti-epileptic medication and without seizure activity&#xD;
             within 1 month are eligible).&#xD;
&#xD;
          3. CNS AML involvement that is symptomatic and in the opinion of the investigator, cannot&#xD;
             be controlled during the interval between enrollment and DARIC T cell infusion&#xD;
&#xD;
          4. If history of allogeneic stem cell transplant: active GVHD, or receiving&#xD;
             immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          5. Presence of active severe infection, defined as:&#xD;
&#xD;
             i. positive blood culture within 48 hours of enrollment, OR ii. fever above 38.2° C,&#xD;
             AND clinical signs of infection within 48 hours of enrollment&#xD;
&#xD;
          6. Primary immunodeficiency syndrome&#xD;
&#xD;
          7. Subject has received prior virotherapy&#xD;
&#xD;
          8. Pregnant or breastfeeding&#xD;
&#xD;
          9. Subject and/or legally authorized representative unwilling to provide consent/assent&#xD;
             for participation in the 15-year follow-up period, required if DARIC T cell therapy is&#xD;
             administered&#xD;
&#xD;
         10. Presence of any condition that, in the opinion of the investigator, would prohibit the&#xD;
             subject from undergoing treatment under this protocol&#xD;
&#xD;
         11. Considered by the investigator to be unable to tolerate a lymphodepleting regimen&#xD;
&#xD;
         12. Subject has a contraindication to receiving rapamycin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Todd Cooper, MD</last_name>
    <phone>206-986-2106</phone>
    <email>CBDCIntake@seattlechildrens.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Todd Cooper, MD</last_name>
      <email>CBDCIntake@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Todd Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Gardner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Rebecca Gardner</investigator_full_name>
    <investigator_title>Medical Director, Immunotherapy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

